Ligand Pharmaceuticals' Q3 2024 earnings report beat on the top and bottom lines, reinforcing my confidence. Read what makes ...

Upcoming data from a mid-stage study of Amgen's experimental weight-loss drug MariTide will shed light on how well it might ...

The world of pharmacenutical stocks has a lot to offer investors. With their resilience in the face of economic issues and ...

Upcoming data from a mid-stage study of Amgen's experimental weight-loss drug MariTide will shed light on how well it might ...

Analyzing Amgen's stock drop, management's response, and potential for growth in GLP-1 candidate MariTide in a volatile ...

Howard Chang will take over as chief scientific officer and senior VP of research as the biotech searches for more ways to ...

Amgen said on Wednesday there was no link between its experimental weight-loss drug and changes in bone density, a day after ...

With the recent spike in implied volatility, an iron condor on Amgen can use short strikes with a wide profit range.

Despite the very positive setup facing Amgen as a result of its ongoing and future investments in developing new ...

In a few weeks, Howard Chang, M.D., Ph.D., will join Amgen, filling both the roles of senior vice president of research and ...

Amgen (AMGN) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.

BMO Capital analyst Evan Seigerman has maintained their bullish stance on AMGN stock, giving a Buy rating yesterday.Don't Miss our Black ...